^
Association details:
| Biomarker: | CDKN2A negative |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck
Published date:
10/04/2022
Excerpt:
Everolimus resulted in significant improvement in PFS for p16-negative patients (n=31) (P=0.031; HR=0.26, 95% CI: 0.07-0.97)...Further, PFS was significantly higher in TP53 mutated (TP53mut) patients treated with everolimus compared to placebo (Log-Rank P=0.027; HR=0.24, 95% CI: 0.06-0.95)....p16-negative and TP53mut patients may benefit from adjuvant treatment with everolimus.
DOI:
10.1158/1078-0432.CCR-21-4290
